IMab (IMAB)
(Delayed Data from NSDQ)
$1.06 USD
+0.02 (1.92%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $1.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
I-Mab Sponsored ADR [IMAB]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Uliledlimab and Givastomig Look to Spearhead US Presence in Time
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
I-Mab?s US Renaissance is in Full Force with Divestment of China Operations and Assets; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
A New Direction For I-Mab Starts to Take Shape, Though Patience is Required; Reit. Buy and Lowering Our PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
I-Mab?s Pipeline Refocusing Hopes to Alleviate Prior Headwinds
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Lemzoparlimab ESMO Data Shines a Positive Light on Embattled CD47 Space; Reit. Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Reprioritized Core of Five Assets Looks to Pave a New Narrative; Reit. Buy and Lowering Our PT to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Reflective of Strong Fundamentals, I-Mab?s Pipeline Aims to Deliver Value Despite Volatile Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Reflections of ASCO ?22 - Part One: Cytokine Modalities Continue to Remain Overlooked
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Uliledlimab ASCO? 22 Update Draws Mixed Sentiment; Reit. Buy and Lowering Our PT to $70 from $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Overreaction to HFCAA Overhang Blinds True Upside Potential; Reit. Buy and Lowering Our PT to $80 from $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Lessening ADR Risk Coupled to CD47 Landscape Dynamics Makes for an Attractive Entry Point
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Pipeline Momentum Continues from All Angles; Reit Buy and Raising PT to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Uliliedlimab?s Displays Positive Efficacy Signals During ASCO 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
I-Mab Hosts R&D Day, Highlighting Multiple Programs From an Expanding Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Multiple Value Drivers Define 2021, Formidable Immuno-Oncology Pipeline Expands; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
I-Mab?s Momentum Far From Terminal Velocity; Reit BUY and Raising PT to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
I-Mab, A Tale of Two Pillars; Initiate With a Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: I-Mab Sponsored ADR
Industry: Medical - Biomedical and Genetics
Reflections on SITC 2020 - Multifaceted Attacks Continue on Cancer.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
|